England Reimburses Ultra-Rare Disease Drug Joenja, While EU Regulatory Review Drags On

 
• By Neena Brizmohun
  
Close-up shot of pills with stamped pound sterling GBP symbol on them
NICE believes that Joenja is cost-effective

More from Health Technology Assessment

More from Rare Diseases